BPC-157 vs TB-500: Which One First? Australian Guide 2025

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

BPC-157 heals locally — it targets the specific tissue you inject near. TB-500 heals systemically — it distributes throughout the body to repair wherever damage exists. They are not competing peptides; they are complementary, and using both is the most effective approach for serious injury. If budget means starting with one, this guide explains which to choose for your specific injury type, what each costs at an Australian compounding pharmacy, and when to add the second.

BPC-157 vs TB-500: the quick comparison

	BPC-157	TB-500
Mechanism	Localised — inject near the target site	Systemic — distributes body-wide
Evidence level	Moderate — 180+ pre-clinical studies	Emerging — strong animal data, limited human RCTs
Best for	Tendon, ligament, gut repair at a specific site	Whole-body inflammation, systemic tissue repair
Typical dose	250–500 mcg/day	5 mg twice weekly (acute); 2.5 mg twice weekly (maintenance)
Cycle	4–8 weeks	4–8 weeks
Monthly cost (AUD)	$140–$200	$180–$260
TGA status	Schedule 4 — prescription required	Schedule 4 — prescription required
Administration	Subcutaneous injection or oral capsule	Subcutaneous injection

What is BPC-157 best for?

BPC-157 (Body Protection Compound 157) was isolated from a gastric protein and has been studied in over 180 pre-clinical trials. Its primary mechanism: stimulating growth hormone receptors, promoting angiogenesis (new blood vessel formation), and upregulating growth factors that accelerate tissue repair at the site of damage.

Where it excels:

Tendon and ligament injuries — the strongest evidence base. Animal studies consistently show accelerated repair of Achilles tendon, rotator cuff, and ACL damage. The localised injection approach (within 5–10 cm of the target tissue, subcutaneous) maximises this effect.
Gut repair — uniquely, BPC-157 is effective orally for gut-related issues. It demonstrates resistance to gastric acid hydrolysis, meaning oral capsules reach the gut lining intact. Used clinically for leaky gut, IBS, and inflammatory bowel conditions.
Acute injuries — the first two weeks of an acute tear or strain are where BPC-157's angiogenic effects are most valuable.

The honest evidence caveat: Over 180 animal studies support BPC-157's mechanisms. One Phase I human trial was completed but results were never published. Human trial evidence is limited — practitioners extrapolate from the robust animal data and case series reports.

What is TB-500 best for?

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring protein that regulates actin polymerisation and drives cell migration to injury sites. Unlike BPC-157, injection location doesn't matter — TB-500 distributes systemically after subcutaneous injection. This is its key practical advantage.

Where it excels:

Whole-body inflammation — athletes with multiple simultaneous injuries, high-volume training loads, or systemic inflammatory conditions benefit most from the systemic distribution
Cardiac and neurological repair — pre-clinical evidence shows meaningful effects in cardiac recovery models and early neurological injury research
Recovery from overtraining — its systemic anti-inflammatory action and cell migration stimulation make it useful when recovery is broadly compromised rather than localised
Injection anxiety — because site doesn't matter, TB-500 is technically easier for beginners. Inject anywhere accessible.

The honest evidence caveat: Pre-clinical data is strong but human RCT evidence is limited. TB-500 is an "emerging evidence" compound on ProtocolHub's scale — the mechanism is well-understood, the animal data is compelling, but long-term human safety data is not yet established.

Head-to-head: cost, access, and evidence in Australia

Both are Schedule 4 in Australia — the same prescription pathway applies. AHPRA-registered telehealth clinic → prescription → licensed compounding pharmacy. The process typically takes 5–10 business days from first consultation.

Cost difference: TB-500 is typically $40–$60 AUD/month more expensive than BPC-157, primarily due to higher synthesis complexity. If budget is the deciding factor, BPC-157 first.

Evidence grade difference: BPC-157 has the stronger human-adjacent evidence base (180+ studies vs TB-500's more limited but growing pre-clinical literature). If conservatism matters, BPC-157 first.

Practical difference: BPC-157 requires injection near the injury site for maximum effect — which means understanding basic injection technique and having a specific target. TB-500 requires no injection site precision — any accessible subcutaneous site works.

Find a prescriber for this protocol in Australia →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

Should you stack them? The Wolverine Protocol explained

Yes — and this is the consensus position among Australian peptide practitioners for serious injuries. The two mechanisms are additive:

BPC-157 works locally at the injury site: angiogenesis, growth factor upregulation, localised tissue repair
TB-500 works systemically: whole-body cell migration, anti-inflammation, general tissue remodelling

Biohacker and athlete Ben Greenfield documented this combination publicly after a torn upper hamstring, reporting recovery "with pretty surprising speed." ProtocolHub has documented this as the Wolverine Recovery Protocol — BPC-157 + TB-500 + GHK-Cu, with optional Ipamorelin/CJC-1295 added at week 2–3 for GH-driven sleep-phase repair.

Full Wolverine Stack cost: $280–$420 AUD/month for BPC-157 + TB-500. Add GHK-Cu for $120–$200 more.

Our recommendation: which to prescribe first for each injury type

Acute tendon or ligament injury (e.g. Achilles, rotator cuff, ACL): Start with BPC-157. Inject subcutaneously within 5–10 cm of the target site. Add TB-500 in week 2 once the acute inflammation phase is establishing.

Gut repair (leaky gut, IBD, IBS): BPC-157 oral capsules — the only scenario where TB-500 is not the better second choice. The oral route delivers directly to the gut lining. TB-500 has no meaningful gut-specific mechanism.

General recovery (overtraining, multiple sites, systemic inflammation): Start with TB-500 — the systemic distribution addresses the whole-body picture. Add BPC-157 for any specific target injury site.

Budget-constrained (one compound only): BPC-157. Stronger evidence base, lower cost, oral capsule option for gut use, and localised injection for musculoskeletal injuries. The most versatile single recovery peptide available in Australia.

How to access either or both in Australia

Both compounds require an AHPRA-registered prescription and must be sourced through a licensed compounding pharmacy. The telehealth pathway typically takes under a week. Specialist peptide clinics — including BioV8 and Thrive Rx — are the most efficient pathway for this type of compound.

ProtocolHub provides educational information only. All peptide therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice.

BPC-157 vs TB-500: Which Recovery Peptide Do Australian Practitioners Prescribe First?